Introduction {#s1}
============

Alzheimer\'s disease (AD) is a devastating neurodegenerative disorder that slowly deprives individuals of their memories and other essential cognitive functions, including executive, visuospatial abilities and language. There is increasing evidence showing that the progression of these cognitive symptoms occurs in an orderly fashion, which reflects the accumulation of amyloid deposits and the spatial distribution of neurofibrillary tangles ([@BHW128C23]). For instance, while memory loss takes place at early disease stages, reflecting the presence of tangles in medial temporal regions ([@BHW128C57]; [@BHW128C68]; [@BHW128C69]); aphasia and apraxia typically occur at later stages, reflecting the spread of tangles and plaques into neocortical areas ([@BHW128C6]; [@BHW128C45]). This incremental spread of pathology between interconnected brain regions suggests that AD might be a disconnection syndrome characterized by abnormalities in brain networks ([@BHW128C89]).

Graph theory has become a very useful tool in neuroimaging to assess the relationship between different brain regions and their organization into large-scale networks ([@BHW128C19]). Using this method, previous studies have shown that healthy individuals have an efficient network topology, combining a high level of integration between distant brain regions (short path length) and a good local communication between neighboring areas (high clustering). This small-world configuration ([@BHW128C36]) is thought to be specially suited for cognitive processing ([@BHW128C3]) and has been shown in previous functional MRI, structural MRI, electroencephalogram, and diffusion tensor imaging (DTI) studies ([@BHW128C84]; [@BHW128C18]; [@BHW128C4]; [@BHW128C37]; [@BHW128C25]). The combination of high efficiency and clustering in a small-world architecture is an attractive principle of brain network organization as it could deliver both segregated and integrated information processing ([@BHW128C10]). For instance, visual processing is a segregated process that would benefit from the clusters of connections between regions that are topologically close, whereas executive processing is an integrated process that would benefit from the long paths that allow transferring information across the whole network ([@BHW128C10]). In addition, it has been shown that regions showing high clustering tend to be very well connected to areas with the same functional specialization ([@BHW128C65]). In line with this, several studies have shown that the brain is organized into communities or modules of interconnected regions ([@BHW128C31]; [@BHW128C47]), which may correspond to large-scale brain systems such as the executive control, the dorsal attention, and the default-mode network. This network property is commonly referred to as modularity and has been shown in healthy individuals by previous studies ([@BHW128C11]; [@BHW128C34]).

Graph theory can be applied to different neuroimaging modalities to assess brain networks in vivo in AD, including DTI, structural, and functional MRI (for reviews, see [@BHW128C71]; [@BHW128C73]; [@BHW128C14]) as well as positron emission tomography (PET) ([@BHW128C56]; [@BHW128C60]; [@BHW128C79]). Using structural MRI, a few studies have shown that AD patients present changes in global network organization compared with healthy controls ([@BHW128C14]; [@BHW128C54]); however, there is surprisingly little agreement about the nature of these changes: while some studies showed an increased path length and clustering in the networks of AD patients, others found decreases or no changes at all ([@BHW128C41]; [@BHW128C14]). Regarding network configuration, some studies using structural MRI have found a preserved small-world organization in AD patients, while others found random or regular network topologies ([@BHW128C14]). This inconsistency between studies could be due to the inclusion of small samples of patients with heterogeneous clinical characteristics. Despite this interest in assessing brain connectivity in AD, to date no studies have assessed modularity in the structural MRI networks of AD patients.

Amnestic mild cognitive impairment (MCI) is a transition state between normal aging and AD with a high risk of progression to dementia ([@BHW128C52]). Although MCI has been associated with reduced white matter integrity and abnormal functional connectivity ([@BHW128C46]; [@BHW128C82]; [@BHW128C53]; [@BHW128C5]), it is not clear whether these patients also present altered brain network topology: [@BHW128C80] found no differences in the path length or clustering between MCI patients and controls, while [@BHW128C54] found differences that varied according to the network construction method. There is increasing evidence showing that MCI patients progress to AD at a rate of approximately 15% per year ([@BHW128C28]). The assessment of network organization in stable MCI patients and those who show a slow or faster progression to dementia is important as it could provide important clues into which network changes mark the transition to AD and improve our understanding on the effects of disease progression on brain networks.

The aim of the current study was to establish the nature of structural abnormalities in the organization of brain networks in stable MCI (sMCI) subjects, patients who show a slow progression to dementia (late MCI converters, lMCIc), patients who show a fast progression to dementia (early MCI converters, eMCIc), and AD patients using graph theory. To achieve this goal, we assessed over 1000 patients and controls from 2 large multicenter cohorts: the Alzheimer\'s Disease Neuroimaging Initiative (ADNI) and the AddNeuroMed study. We calculated various global and local network measures, including the characteristic path length, the mean clustering coefficient, the small-worldness, the nodal clustering, and the nodal closeness centrality. In addition, in contrast to previous studies, we calculated for the first time the transitivity and modularity in the structural MRI networks of MCI and AD patients. These graph theory measures reflect how well a region is connected to its neighbouring areas and within brain modules, providing important information on the network\'s ability for specialized processing to occur within densely interconnected groups of brain regions ([@BHW128C55]). We hypothesized that global network measures would show abnormalities across all patient groups, with lMCIc, eMCIc, and AD patients showing more severe network changes compared with controls than sMCI patients. In addition, based on previous evidence showing that the sequence of brain abnormalities between regions of the default-mode network is reminiscent of the spread of tangle pathology in AD ([@BHW128C9], [@BHW128C8]), we hypothesized that patients would show changes in local network measures in the regions of this network.

Methods {#s2}
=======

Subjects {#s2a}
--------

Data used in the preparation of this article were obtained from the ADNI database (adni.loni.usc.edu) and the AddNeuroMed study. In total, 1008 subjects were included, consisting of 301 controls, 425 MCI, and 282 AD patients. Regarding MCI patients, 87 converted to AD after 1 year (eMCIc), 71 converted to AD after 3 years (lMCIc), and 110 remained stable after 3 years (sMCI). In addition, 157 MCI patients remained stable after 1 year but had no additional follow-ups after that period. We classified these subjects as sMCI-1y and compared them with the other groups in a supplementary analysis. Eight subjects were excluded from the previous groups due to uncertain diagnosis.

The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI), PET, other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of MCI and early AD. In the ADNI cohort, the inclusion criteria for the control group were Mini-Mental State Examination (MMSE) scores between 24 and 30, a Clinical Dementia Rating-Sum of Boxes (CDR-SB) score of 0, and lack of depression, MCI, or dementia. Inclusion criteria for the MCI group followed the Peterson criteria ([@BHW128C52]) for amnestic MCI. AD participants met the National Institute for Neurological and Communicative Disorders and Stroke-Alzheimer\'s Disease and Related Disorder Association (NINDS/ADRDA) criteria for probable AD, had a MMSE score between 18 and 26, and a CDR-SB of 0.5--1.0. Exclusion criteria comprised history of structural brain lesions or head trauma, significant neurological disease other than incipient AD, and the use of psychotropic medications that could affect memory. For up-to-date information about the ADNI study, see [www.adni-info.org](www.adni-info.org).

AddNeuroMed is an Integrated Project funded by the European Union Sixth Framework program ([@BHW128C44], [@BHW128C43]). AddNeuroMed aims to develop and validate novel surrogate markers of disease and treatment, based upon in vitro and in vivo models in animals and humans in AD. The neuroimaging part of AddNeuroMed uses MRI and magnetic resonance spectroscopy (MRS) to establish imaging markers for early diagnosis and detection of disease and efficacy of disease modifying therapy in man, as well as translational imaging biomarkers in animal models of AD. Human data were collected from 6 different sites across Europe: University of Kuopio (Finland), University of Perugia (Italy), Aristotle University of Thessaloniki (Greece), King\'s College London (United Kingdom), University of Lodz (Poland), and University of Toulouse (France) ([@BHW128C43]; [@BHW128C63], [@BHW128C62]). The inclusion criteria for the control group were Mini-Mental State Examination (MMSE) scores between 24 and 30, a CDR score of 0, 65 years, or above, and lack of depression, dementia, other neurological diseases, unstable systematic illnesses, or organ failure. The inclusion criteria for MCI patients were similar to the control group except for the CDR score of 0.5 and report of memory problems by the patient or informant. AD patients met the NINDS/ADRDA and DSM-IV criteria for probable AD, had a MMSE score between 12 and 28, had 65 years or above, and did not have significant neurological or psychiatric illnesses other than AD, unstable systematic illnesses, or organ failure.

MRI Acquisition {#s2b}
---------------

Data acquisition for the AddNeuroMed study was designed to be compatible with ADNI ([@BHW128C85]; [@BHW128C63], [@BHW128C62]). In particular, all participants, both from ADNI and AddNeuroMed, were scanned on a 1.5 Tesla MRI system using a sagittal 3D *T*~1~-weighted MPRAGE sequence: repetition time (TR) = 9--13 ms; echo time (TE) = 3.0--4.1 ms; inversion time (IT) = 1000 ms; flip angle (FA) = 8°; voxel size = 1.1 × 1.1 × 1.2 mm^3^. Images from ADNI were acquired in 58 sites, while images from AddNeuroMed were acquired in 5 sites or centers. We have combined these 2 cohorts in several previous studies ([@BHW128C67]; [@BHW128C17]), showing that they present similar patterns of atrophy and predictive power in discriminating patients with AD or MCI from controls ([@BHW128C75]).

Image Preprocessing {#s2c}
-------------------

All *T*~1~-weighted images were preprocessed using the FreeSurfer software, version 5.1. Briefly, preprocessing included: correction of motion artifacts and spatial distortions due to gradient nonlinearity and B1 field inhomogeneity; removal of nonbrain tissue using a hybrid watershed/surface deformation procedure ([@BHW128C58]); automated transformation into the Talairach standard space; intensity normalization ([@BHW128C64]); tessellation of the gray/white matter boundary; automated topology correction ([@BHW128C59]); and surface deformation following intensity gradients to optimally place the gray/white and gray/CSF borders at the location where the greatest shift in intensity defines the transition to the other tissue class ([@BHW128C20]). Once the cortical models were complete, registration to a spherical atlas took place, which utilizes individual cortical folding patterns to match cortical geometry across subjects ([@BHW128C21]). This was followed by parcellation of the cerebral cortex into 68 cortical regions using the atlas by [@BHW128C15] (Fig. [1](#BHW128F1){ref-type="fig"}). In addition to these 68 regions, 7 subcortical structures were also included: hippocampus, amygdala, thalamus, caudate, putamen, accumbens, and pallidum (Fig. [1](#BHW128F1){ref-type="fig"}). All data was preprocessed through the HiveDB database system ([@BHW128C48]). We excluded 8 subjects that were outliers in cortical thickness and subcortical volume measures. Figure 1.Brain regions used in network construction and analysis. The cortical thickness and subcortical volumes were extracted from these regions for every subject.

Network Construction and Analysis {#s2d}
---------------------------------

For every cortical region, a linear regression was performed to control for the effects of age, gender, and education ([@BHW128C32]). The same procedure was carried out for subcortical regions including intracranial volume as an additional covariate. To ensure that our results were not influenced by the fact that subjects were scanned at different centers, we included scanning site as an additional covariate in a supplementary analysis.

The residuals of these regressions were used to substitute the raw values and build the structural covariance networks. In these networks, every node corresponded to a brain region and the edges represented the correlations between them ([@BHW128C32]). In this study, both cortical thicknesses and subcortical volumes were used to build the structural networks due to previous evidence showing the involvement of cortical and subcortical regions in MCI and AD and similarly to previous graph theory studies ([@BHW128C35]; [@BHW128C51]).

For every group, we built an 82 × 82 association matrix, where each entry was defined as the Pearson correlation coefficient between corrected anatomical measures of every pair of regions across participants (Fig. [2](#BHW128F2){ref-type="fig"}). For each association matrix, a binary matrix was computed, where the correlation coefficient was considered 1 if it was above a threshold and 0 if it was below ([@BHW128C32]). Since thresholding association matrices of different groups may yield networks with a different number of nodes and edges, we thresholded the association matrices at a range of network densities *D* (*D* min = 5% to *D* max = 35%, in steps of 1%) and compared the network topologies across that range. For densities below 5%, the number of edges was inferior to the number of nodes, corresponding to a widely disconnected network. For *D* above 35%, the networks became similar to random graphs and showed a small-world index close to 1. All self-connections and negative correlations were excluded from the analyses. Figure 2.Structural correlation matrices for (*A*) controls (CTR), (*B*) patients with stable mild cognitive impairment after 1 year (sMCI-1y), (*C*) patients with sMCI (after 3 years), (*D*) lMCIc, (*E*) eMCIc, and (*F*) AD patients. In these matrices, the first rows and columns correspond to the correlations between cortical regions, while the last ones correspond to the correlations between subcortical areas. The color bar indicates the strength of the correlation coefficients: warmer colors represent stronger correlations, while colder colors represent weaker correlations.

To detect differences between groups in global network topology, we calculated the characteristic path length, the mean clustering coefficient, the transitivity, the modularity, and the small-worldness. The characteristic path length is the average shortest path length between all pairs of nodes in the network and indicates how easy it is (on average) to reach a node from any other node in the network ([@BHW128C74]); this measure was calculated only within connected components of the network as implemented in the formulas by [@BHW128C55]. The clustering coefficient is the average over the whole network of the fraction of a node\'s neighbors that are also neighbors of each other; it reflects how well the nodes are connected to nearby regions forming clusters ([@BHW128C74]). The transitivity is similar to the clustering coefficient but, instead of being normalized individually by every node, it is normalized by the whole network and is not influenced by nodes with a low degree ([@BHW128C87]). The modularity describes the extent to which a network can be divided into modules or communities of regions with a large number of within-modules connections and a minimal number of between-module connections ([@BHW128C50]). The small-worldness is a measure of how much a network is locally interconnected compared with a random network but still retaining global connectivity between distant brain regions ([@BHW128C74]; [@BHW128C36]).

To assess differences between groups in regional network topology, we calculated the nodal clustering and the closeness centrality. We selected these 2 nodal network measures, because they are sensitive to different aspects of network topology and remain largely unexplored in MCI and AD. Specifically, the nodal clustering is a measure of segregation, which reflects the ability for specialized information processing to occur within groups of brain regions, while the closeness centrality is a measure of interaction that reflects the ability to combine information from distributed brain areas ([@BHW128C55]). The nodal clustering is calculated as the mean clustering coefficient but only for a given node. The closeness centrality is the inverse of the average shortest path length from 1 node to all other nodes in the network. To compare the roles of the nodes in each module and their differences between groups, we also calculated the within-module degree and participation coefficient. The within-module degree measures the connectivity of the node within the module compared with the other nodes in the same module. The participation coefficient expresses how strongly a node is connected to other modules and tends to 1 if a node has a homogeneous connection distribution with all the modules and 0 if it does not have any intermodule connections ([@BHW128C29]; [@BHW128C30]).

The formulas that were used to calculate the global and nodal graph theory measures are provided by [@BHW128C55]. We used BrainNet Viewer (<http://www.nitrc.org/projects/bnv/>) for network visualization ([@BHW128C77]).

Comparison of Network Measures Between Groups {#s2e}
---------------------------------------------

We tested the statistical significance of the differences between groups using nonparametric permutation tests with 1000 permutations ([@BHW128C4]; [@BHW128C33]). In each permutation, the corrected anatomical values of every subject were randomly reassigned to one of a pair of groups with the same number of subjects as in the original groups. Then, an association matrix was built for each pair of randomized groups, and the binary matrices were calculated at a range of network densities. The network measures were calculated at each density, and the differences between the new randomized groups were computed. This randomization procedure was repeated 1000 times for every density value, and the 95% confidence intervals (CI) of each distribution were used as critical values for a 2-tailed test of the null hypothesis at *P* \< 0.05. To correct the nodal network results for multiple comparisons, we used a false discovery rate (FDR) procedure ([@BHW128C24]) at a *q* value of 0.05.

Results {#s3}
=======

The characteristics of the sample can be found in Table [1](#BHW128TB1){ref-type="table"}. There were significant differences in gender and years of education between the groups (*P* \< 0.001). For this reason, the cortical thickness and subcortical measures were corrected by these variables in the current study. As expected, all patient groups showed lower MMSE scores (*P* \< 0.001) and higher CDR scores (*P* \< 0.001) compared with controls. In addition, lMCIc, eMCIc, and AD patients showed lower MMSE scores compared with sMCI patients (*P* \< 0.05). AD patients showed worse MMSE scores compared with sMCI, lMCIc, eMCIc patients (*P* \< 0.05), and sMCI-1y patients had lower MMSE scores compared with sMCI patients (*P* \< 0.05). Table 1Characteristics of the sampleCTR (*n* = 301)sMCI-1y (*n* = 157)sMCI (*n* = 110)lMCIc (*n* = 71)eMCIc (*n* = 87)AD (*n* = 282)*F* or *χ*^2^ (*P* value)Age75.1 (5.7)75.0 (6.5)74.7 (7.5)74.8 (7.0)74.1 (6.7)75.6 (7.0)0.9 (0.475)Gender (m/f)^a,b,c,d,e^156/14588/6974/3643/2854/33130/15219.2 (0.002)Education (y)^f,a,g,h,i,j,k,l,c,m,d,e^14.2 (4.4)11.8 (5.2)15.7 (3.0)16.1 (3.0)13.9 (4.2)12.2 (4.9)21.2 (\<0.001)MMSE^f,a,g,n,h,i,b,o,l,c,d,e^29.1 (1.1)27.0 (1.6)27.6 (1.7)26.7 (1.7)26.6 (1.8)22.4 (3.5)272.8 (\<0.001)CDR^f,a,g,n,h,b,c,d,e^00.50.50.50.50.9 (0.4)880.2 (\<0.001)[^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13][^14][^15][^16][^17]

Global Network Analysis {#s3a}
-----------------------

The weighted correlation matrices for each group are presented in Figure [2](#BHW128F2){ref-type="fig"}. We observed that the correlation patterns of all groups showed strong correlations between bilaterally homologous regions.

In general, with progressively higher values of network density (*D*), the characteristic path length and modularity decreased, the mean clustering coefficient and transitivity increased, and a small-world topology was observed across all groups (Fig. [3](#BHW128F3){ref-type="fig"}). Figure 3.Changes in global network measures as a function of network density. Characteristic path length (*A*), clustering coefficient (*B*), transitivity (*C*), modularity (*D*), and small-worldness (*E*) for controls (CTR), patients with stable mild cognitive impairment after 1 year (sMCI-1y), patients with sMCI (after 3 years), lMCIc, eMCIc, and AD patients.

Our statistical analyses showed significant increases in the characteristic path length in the sMCI, lMCIc, eMCIc, and AD groups compared with controls at several network densities (*P* range, 0.043--0.001) (Fig. [4](#BHW128F4){ref-type="fig"}). The clustering coefficient also showed significant changes, being decreased across different densities in lMCIc, eMCIc, and AD (*P* range, 0.043--0.001) but not in sMCI patients, compared with controls. The transitivity and modularity showed the greatest differences between patients and controls: the transitivity was significantly decreased (*P* range, 0.049--0.001) and the modularity was significantly increased (*P* range, 0.049--0.001) in patients at most network densities (Fig. [4](#BHW128F4){ref-type="fig"}). We also found significant decreases in the small-worldness in the patient groups compared with controls (*P* range, 0.040--0.010); however, these differences were only observed at a few network thresholds (Fig. [4](#BHW128F4){ref-type="fig"}). Figure 4.Differences between controls, sMCI, lMCIc, eMCIc, and AD patients in global network measures. Plots showing the differences between controls (CTR) and sMCI patients; CTR and lMCIc; CTR and eMCIc; CTR and AD patients in the characteristic path length (*A*), clustering coefficient (*B*), transitivity (*C*), modularity (*D*), and small-worldness (*E*). The plots show the upper and lower bounds of the 95% confidence intervals (CI) (in gray) and the differences in the network measures between groups (in orange circles) as a function of network density. If these differences fall outside the CIs, there is a statistical significant difference at *P* \< 0.05.

When we compared the different patient groups, we observed that lMCIc, eMCIc, and AD patients had a decreased characteristic path length (*P* range, 0.048--0.001) and clustering coefficient (*P* range, 0.042--0.001) compared with sMCI patients (Fig. [5](#BHW128F5){ref-type="fig"}). There were no significant differences in transitivity or modularity between these groups. In addition, there were no differences in global network topology between lMCIc, eMCIc, and AD patients. Figure 5.Differences between sMCI, lMCIc, eMCIc, and AD patients in global network measures. Plots showing the differences between sMCI and lMCIc patients; sMCI and eMCIc patients; sMCI and AD patients in the characteristic path length (*A*) and clustering coefficient (*B*). The plots show the upper and lower bounds of the 95% confidence intervals (CI) (in gray) and the differences in the network measures between groups (in orange circles) as a function of network density. If these differences fall outside the CIs, there is a statistical significant difference at *P* \< 0.05.

The global network comparisons carried out in the sMCI-1y group can be found in [Supplementary Figure 1](http://cercor.oxfordjournals.org/lookup/suppl/doi:10.1093/cercor/bhw128/-/DC1). These patients showed evidence of larger paths (*P* range, 0.045--0.004) and changes in the clustering (*P* range, 0.044--0.018) at a few network thresholds, but no changes in the transitivity or modularity compared with controls, in contrast to the other MCI groups. They also showed higher clustering compared with eMCIc (*P* range, 0.046--0.018) and AD patients (*P* range, 0.043--0.016) and higher transitivity (*P* range, 0.048--0.019) compared with AD patients at several densities. The modularity and small-worldness did not show significant changes in sMCI-1y compared with the other patient groups.

To assess whether our results were influenced by different scanning centers, we repeated the analyses comparing controls to the patient groups after including the centers as an additional covariate. These analyses showed similar differences in the characteristic path length, mean clustering, transitivity, and modularity between patients and controls, suggesting that the differences in scanning sites did not influence our results (see [Supplementary Table 1](http://cercor.oxfordjournals.org/lookup/suppl/doi:10.1093/cercor/bhw128/-/DC1)).

Nodal Network Analysis {#s3b}
----------------------

We identified several changes in nodal network measures between groups. In summary, the nodal clustering was decreased in patients compared with controls and showed widespread changes only in the AD group. The nodal closeness centrality was decreased in the bilateral hippocampi and amygdala across all patient groups and showed increases in medial parietal, medial temporal, and limbic regions that varied according to the patient group. Below, we describe these changes in greater detail.

After correcting for multiple comparisons (FDR, *q* \< 0.05), we observed that sMCI patients showed clustering decreases in the left superior frontal gyrus, while eMCIc patients showed decreases in the right postcentral gyrus compared with controls. In AD patients, the nodal clustering decreases involved several regions: the bilateral precuneus, superior frontal gyri, lateral orbitofrontal gyri, middle temporal gyri, inferior temporal gyri, fusiform, hippocampi, and amygdala; the left pars triangularis gyrus, postcentral gyrus; and the right caudal middle frontal gyrus, pars opercularis gyrus, and lateral occipital gyrus (Fig. [6](#BHW128F6){ref-type="fig"} and Table [2](#BHW128TB2){ref-type="table"}). AD patients also showed significant clustering decreases in the left postcentral gyrus compared with sMCI patients (FDR, *q* \< 0.05). Table 2Significant differences in the nodal clustering coefficient between groups (FDR-corrected)RegionCTRsMCI*P* valueLh Superior frontal G0.830.500.002CTReMCIcRh Postcentral0.940.560.001CTRADLh Superior frontal G0.830.570.001Lh Lateral orbitofrontal G0.810.510.001Lh Pars triangularis G0.900.650.001Lh Postcentral G0.960.680.001Lh Precuneus0.780.580.001Lh Middle temporal G0.780.620.017Lh Inferior temporal G0.940.640.002Lh Fusiform0.790.560.004Lh Hippocampus10.330.001Lh Amygdala10.330.001Rh Superior frontal G0.780.520.001Rh Caudal middle frontal G0.920.770.009Rh Lateral orbitofrontal G0.710.450.003Rh Pars opercularis G0.960.620.001Rh Precuneus0.800.620.017Rh Lateral occipital G0.740.600.007Rh Middle temporal G0.810.610.016Rh Inferior temporal G0.900.660.003Rh Fusiform0.840.530.001Rh Hippocampus10.330.001Rh Amygdala10.330.001sMCIADLh Postcentral0.950.680.001[^18] Figure 6.Significant decreases in the nodal clustering coefficient in sMCI, eMCIc, and AD patients. CTR, controls; sMCI, stable MCI; eMCIc, early MCI converters, AD, Alzheimer\'s disease. The regions showing clustering decreases in patients are listed in Table [2](#BHW128TB2){ref-type="table"}.

Regarding the closeness centrality, in addition to the significant decreases found in the hippocampi and amygdala in sMCI, lMCIc, eMCI, and AD patients compared with controls, there were additional decreases in the right pericalcarine gyrus in sMCI and lMCIc patients; the right accumbens in eMCIc patients. The increases in closeness centrality were observed in the left posterior cingulate in sMCI patients; the left pallidum, right insula, right temporal pole, right entorhinal in lMCIc patients; the left posterior cingulate, right lateral orbitofrontal gyrus, bilateral insula, bilateral entorhinal in AD patients (Fig. [7](#BHW128F7){ref-type="fig"} and Table [3](#BHW128TB3){ref-type="table"}). Table 3Significant differences in the nodal closeness centrality between groups (FDR-corrected)RegionCTRsMCI*P* valueLh Posterior cingulate0.300.480.001Lh Hippocampus10.290.001Lh Amygdala10.340.001Rh Pericalcarine0.380.280.001Rh Hippocampus10.380.001Rh Amygdala10.330.001CTRlMCIcLh Pallidum0.3910.001Lh Hippocampus10.390.001Lh Amygdala10.340.001Rh Insula0.280.530.001Rh Pericalcarine0.380.300.001Rh Temporal pole0.290.460.001Rh Entorhinal0.220.450.001Rh Hippocampus10.440.001Rh Amygdala10.330.001CTReMCIcLh Posterior cingulate0.300.540.001Lh Lingual G0.430.560.001Lh Temporal pole0.390.490.001Lh Hippocampus10.260.001Lh Amygdala10.350.001Lh Accumbens0.3610.001Rh Insula0.280.490.001Rh Temporal pole0.290.450.001Rh Entorhinal0.220.460.001Rh Hippocampus10.320.001Rh Amygdala10.320.001Rh Accumbens0.5410.001CTRADLh Insula0.380.510.001Lh Posterior cingulate0.300.550.001Lh Entorhinal0.290.440.001Lh Hippocampus10.310.001Lh Amygdala10.310.001Rh Lateral orbitofrontal G0.470.580.006Rh Insula0.280.530.001Rh Entorhinal0.220.440.001Rh Hippocampus10.310.001Rh Amygdala10.310.001sMCIlMCIcLh Postcentral G0.410.580.005Lh Pallidum0.2110.001Rh Postcentral0.410.610.001sMCIeMCIcLh Pericalcarine0.260.410.001Lh Transverse temporal G0.400.540.001Lh Accumbens0.2110.001Rh Lingual G0.320.500.001Rh Accumbens0.2110.001sMCIADLh Postcentral G0.410.600.001Lh Pallidum0.2110.001Rh Pericalcarine0.280.370.001Rh Pallidum0.2110.001lMCIceMCIcLh Accumbens0.3010.001eMCIcADLh Lingual0.550.430.001Rh Frontal pole0.340.450.001[^19] Figure 7.Significant differences in the closeness centrality between controls and sMCI, lMCIc, eMCIc, and AD patients. CTR, controls; sMCI, stable mild cognitive impairment; lMCIc, late MCI converters; eMCIc, early MCI converters; AD, Alzheimer\'s disease. The regions showing significant closeness centrality decreases are colored in blue, while the regions showing closeness centrality increases in patients are colored in orange. These regions are listed in Table [3](#BHW128TB3){ref-type="table"}.

There were also significant differences in closeness centrality between the patient groups, mostly in temporal, occipital, and subcortical regions (for further details, see Table [3](#BHW128TB3){ref-type="table"}).

In Table [4](#BHW128TB4){ref-type="table"}, we present a summary of the most relevant global and nodal network results found in the current study. Table 4Summary of the most relevant global and nodal network resultsMeasuresCTR vs. sMCICTR vs. lMCIcCTR vs. eMCIcCTR vs. ADsMCI vs. lMCIcsMCI vs. eMCIcsMCI vs. ADCharacteristic path length↑↑↑↑↓↓↓Clustering coefficient---↓↓↓↓↓↓Transitivity↓↓↓↓---------Modularity↑↑↑↑---------Small-worldness↓↓↓↓---------Nodal clustering↓\
1 region---↓\
1 region↓\
21 regions------↓\
1 regionNodal closeness centrality↓\
5 regions↓\
5 regions↓\
4 regions↓\
4 regions---------↑\
1 region↑\
4 regions↑\
8 regions↑\
6 regions↑\
3 regions↑\
5 regions↑\
4 regions[^20]

Brain Modules {#s3c}
-------------

We identified 4 modules in controls; 3 modules in sMCI, lMCIc, and eMCIc patients; and 5 modules in AD patients (Fig. [8](#BHW128F8){ref-type="fig"}). For a full list of the regions belonging to each module, see Table [5](#BHW128TB5){ref-type="table"}. Table 5Brain modules in controls, sMCI, lMCIc, eMCIc, and AD patientsHemisphereBrain regionModules CTRModules sMCIModules lMCIcModules eMCIcModules ADLeftSuperiorfrontalIIIIIIIIIIIIILeftFrontalpoleIIIIIIILeftRostralmiddlefrontalIIIIIIIIIIIILeftCaudalmiddlefrontalIIIIIIIIIIIIIIILeftParsorbitalisIIIIIIIIILeftLateralorbitofrontalIIIIILeftParstriangularisIIIIIIIIIIILeftParsopercularisIIIIIIIIIIILeftMedialorbitofrontalIIIIILeftRostralanteriorcingulateIIIIILeftCaudalanteriorcingulateIIIIIILeftInsulaIIIIIILeftPrecentralIIIIIIIIIIIIILeftPostcentralIIIIIIIIIIIIIIILeftSupramarginalIIIIIIIIIIILeftSuperiorparietalIIIIIIIIIIIIIIILeftInferiorparietalIIIIIIIIIIIIIIILeftParacentralIIIIIIIIIIIIIIILeftPosteriorcingulateIIIIIIIIIILeftIsthmuscingulateIIIIIIIILeftPrecuneusIIIIIIIIIIIIIIILeftCuneusIIIIIIIIIIIIIIILeftPericalcarineIIIIIIIIIIIIIIILeftLingualIIIIIIIIIIIIIILeftLateraloccipitalIIIIIIIIIIIIIIILeftTransversetemporalIIIIIIIIIIIIILeftBanksstsIIIIIIIIIIIIIIILeftSuperiortemporalIIIIIIIIIIIIILeftMiddletemporalIIIIIIIIIILeftInferiortemporalIIIIIIIIIIIILeftTemporalpoleIIIIIIIVLeftEntorhinalIIIIIIIIVLeftParahippocampalIVIIIIIIVLeftFusiformIIIIIIIIIIILeftThalamusIIIIIIIIVILeftCaudateIIIIIIIIIILeftPutamenIIIIIIIIIILeftPallidumIIIIIIIIIILeftHippocampusIIIIIIIIVLeftAmygdalaIIIIIIIIVLeftAccumbensIIIIIIIIIIRightSuperiorfrontalIIIIIIIIIRightFrontalpoleIIIIIIIRightrostralmiddlefrontalIIIIIIIIIRightCaudalmiddlefrontalIIIIIIIIIIIIIIIRightParsorbitalisIIIIIIIRightLateralorbitofrontalIIIIIIRightParstriangularisIIIIIIIIIRightParsopercularisIIIIIIIIIIIIIIIRightMedialorbitofrontalIIIIIIIIRightRostralanteriorcingulateIIIIIRightCaudalanteriorcingulateIIIIIRightInsulaIIIIIIIRightPrecentralIIIIIIIIIIIIIRightPostcentralIIIIIIIIIIIIIIIRightSupramarginalIIIIIIIIIIIIIRightSuperiorparietalIIIIIIIIIIIIIIIRightInferiorparietalIIIIIIIIIIIIIIIRightParacentralIIIIIIIIIIIIIIIRightPosteriorcingulateIIIIIIIIIRightIsthmuscingulateIIIIIIIIRightPrecuneusIIIIIIIIIIIIIIIRightCuneusIIIIIIIIIIIIIIIRightPericalcarineIIIIIIIIIIIIIIIRightLingualIIIIIIIIIIIIIIIRightLateraloccipitalIIIIIIIIIIIIIIIRightTransversetemporalIIIIIIIIIIIRightBanksstsIIIIIIIIIIIIIRightSuperiortemporalIIIIIIIVRightMiddletemporalIIIIIIVRightInferiortemporalIIIIIIIIIRightTemporalpoleIIIIIIIVRightEntorhinalIIIIIIIIVRightParahippocampalIVIIIIIIVRightFusiformIIIIIIIVRightThalamusIIIIIIIIVIRightCaudateIIIIIIIIIIRightPutamenIIIIIIIIIIRightPallidumIIIIIIIIIIRightHippocampusIIIIIIIIVRightAmygdalaIIIIIIIIVRightAccumbensIIIIIIIIII[^21] Figure 8.Brain modules in controls and sMCI, lMCIc, eMCIc, and AD patients. CTR, controls; sMCI, stable mild cognitive impairment; lMCIc, late MCI converters; eMCIc, early MCI converters; AD, Alzheimer\'s disease. Four modules were identified in the networks of CTR; 3 modules were identified in sMCI, lMCIc, and eMCIc patients; 5 modules were identified in the networks of AD patients. For each group, the left and right lateral (top) and medial (bottom) brain views are shown.

Briefly, in controls, Module I included the superior frontal gyri, posterior cingulate, and supramarginal gyri, which are part of the default-mode network. Module II included the entorhinal gyri and subcortical regions. Module III was the largest, including several lateral frontal, parietal, and occipital regions. Module IV included the parahippocampal gyri.

In sMCI, lMCIc, and eMCIc patients, the modules were similar to those in controls. However, Module I did not include the superior frontal, lateral parietal, or posterior parietal regions and Module II included additional areas in the patient groups. In AD patients, Module II lost several regions that formed 2 new modules, which were not present in the other groups: one composed of the caudate, putamen, accumbens, and pallidum (Module IV) and the other composed of the bilateral thalami (Module V).

To assess differences between groups in the previous modules, we measured the within-module degree and participation coefficient. We found significant increases in the within-module degree and decreases in the participation coefficient in AD patients compared with controls, after FDR corrections (Table [6](#BHW128TB6){ref-type="table"}). The within-module degree increases were observed in the left postcentral, left superior parietal, right pars opercularis gyri, and right insula, which were part of Module I and Module III. The participation coefficient decreases were observed in the left pars orbitalis and bilateral cuneus, which were part of Module III. Although they did not survive correction for multiple comparisons, lMCIc and eMCIc patients also showed within-module degree increases and participation coefficient decreases in some of these regions, compared with controls (Table [6](#BHW128TB6){ref-type="table"}). Table 6Differences in the within-module degree and participation coefficient between groupsWithin-module degreeCTRlMCIc*P* valueRegion Rh Pars opercularis G−3.290.530.002Within-module degreeCTReMCIc*P* valueRegion Lh Postcentral G−0.351.220.004 Lh Superior Parietal G−0.350.990.017Within-module degreeCTRAD*P* valueRegion Lh Postcentral G−1.120.700.001 Lh Superior Parietal G−1.120.890.002 Lh Superior Temporal G0.391.860.003 Rh Pars Opercularis G−2.810.420.001Participation coefficientCTRAD*P* valueRegion Lh Lateral Occipital G0.660.230.004 Rh Postcentral G0.660.240.008 Rh Lateral Occipital G0.660.320.001[^22]

Discussion {#s4}
==========

This study is the largest to date to assess network topology in MCI patients that remain stable, show a slow or fast progression to dementia as well as AD patients. Our findings revealed an abnormal organization in the networks of all patient groups as reflected by an increased path length, reduced transitivity, and increased modularity, compared with controls. The clustering coefficient showed a different pattern, being decreased in lMCIc, eMCIc, and AD but not in sMCI patients. Altogether, these findings suggest that the prodromal and clinical stages of AD are associated with a reduced ability to integrate information across distributed brain regions and an altered communication between neighboring areas and modules.

In the current study, we found a larger path length across all patient groups compared with controls, indicating an abnormal global network organization. Previous evidence suggests that a short path length ensures rapid information transmission across remote brain regions that are thought to be the basis of cognitive functioning ([@BHW128C66]). The path length increases found in our study show that the distance between any 2 regions was greater in the patient\'s networks, making the communication between them less efficient. This finding is in line with those of previous graph theory studies in AD, which found an increased path length in the structural and functional networks of these patients ([@BHW128C33]; [@BHW128C42]; [@BHW128C90]; [@BHW128C80]; [@BHW128C61]). In one of these studies using DTI to build individual white matter networks, the path length increases were associated with worse MMSE performance ([@BHW128C61]), suggesting that this measure might indeed be a marker of cognitive dysfunction in AD.

Our analyses also showed decreases in the mean clustering coefficient in lMCIc, eMCIc, and AD patients relative to controls, indicating that there were fewer connections between neighboring areas in their networks. This result is in line with some ([@BHW128C71]; [@BHW128C73]) but not all previous studies ([@BHW128C33]; [@BHW128C80]), suggesting that differences in methodology, sample sizes, and patient characteristics might lead to different network findings. In a previous study, [@BHW128C41] found that MCI converters presented longitudinal decreases of the clustering coefficient suggesting that reductions in this network measure are associated with conversion to dementia in AD.

Furthermore, our study is the first to assess transitivity and modularity in the structural networks of MCI and AD patients. We found that these measures identified greater abnormalities in the networks of all patient groups compared with the path length or clustering, reaching significance across most network densities. Similarly to the clustering coefficient, the transitivity is a measure that reflects how well a region is integrated within its local cluster. However, in contrast to the clustering, the transitivity is less influenced by nodes with fewer connections ([@BHW128C55]), being a superior measure in networks with poorly connected nodes. Hence, we recommend the use of this measure in future studies assessing structural networks in amnestic MCI and AD as it offers greater sensitivity to the effects of the disease. The modularity is a more sophisticated measure that describes the existence of communities of regions within the network ([@BHW128C49]). This network measure increases when brain regions are well connected within their module but are poorly connected with regions belonging to other modules. In the current study, we found significant modularity increases in sMCI, lMCIc, eMCIc, and AD patients compared with controls, indicating higher intramodule connectivity and lower connectivity between modules. This finding indicates that there is a worse communication between modules in patients, suggesting that their whole-brain networks were fragmented into a few large, isolated components. The within-module degree increases and participation coefficient decreases we found in frontal, parietal, and occipital regions in the patient groups compared with controls further confirm that the modules were well connected within themselves but not between each other in patients. In a previous fMRI study, significant modularity increases were also found in patients with Parkinson\'s disease with mild cognitive impairment, who have a higher risk of developing dementia ([@BHW128C2]). These increases in modularity can be interpreted as an abnormal process by which the connections between brain areas belonging to a certain module increase, leaving the other modules relatively isolated. In that study, the abnormal modularity increases were associated with worse memory and visuospatial performance in Parkinson\'s patients, confirming they were pathological and related to greater clinical decline ([@BHW128C2]). In our study, we also observed that, despite having similar modules to controls, the regions belonging to each module changed across the patient groups, with AD patients showing 2 modules that were not present in the other groups. Hence, our findings suggest that there is a reorganization of the modules in sMCI, lMCIc, eMCIc, and AD patients. Similarly to previous studies assessing modularity in structural MRI networks ([@BHW128C11], [@BHW128C12]; [@BHW128C76]), we did not find an exact correspondence between the brain modules and previously reported resting-state fMRI networks ([@BHW128C26]).

In addition to global network changes, we also observed alterations in the topology of specific brain regions. We found there were decreases in the nodal clustering of several areas in AD patients compared with controls, indicating worse local communication between neighboring areas. Some of these areas belonged to the default-mode network and included the precuneus and superior frontal gyri ([@BHW128C26]), in line with our initial hypothesis and with previous studies showing pathological changes within this network in AD ([@BHW128C9], [@BHW128C8]; [@BHW128C40]). In addition, we also observed clustering decreases in other frontal and temporal regions in AD patients, suggesting that the regional clustering changes were quite widespread, in line with evidence showing extended brain atrophy at advanced stages of AD ([@BHW128C39]). The MCI patient groups only showed clustering decreases in a few frontal and parietal regions, in contrast with the widespread changes observed in AD patients.

The nodal closeness centrality showed both increases and decreases in sMCI, lMCIc, eMCIc, and AD patients compared with controls. The decreases were mainly observed in the bilateral hippocampi and amygdala across all patient groups, indicating a loss of number of connections between these structures and other regions of the network. This could be related to white matter integrity loss or disruption of white matter fibers connecting these brain areas, which has been previously observed in MCI and AD patients in DTI studies (for a review, see [@BHW128C13]). The increases of closeness centrality were mainly observed in the posterior cingulate, temporal pole, entorhinal cortex, insula, and orbitofrontal regions. The closeness centrality is a measure of interaction between regions; the fact that it is increased in regions showing pathological changes in AD ([@BHW128C7]; [@BHW128C68]; [@BHW128C23]) could be related to shared mechanisms in neurodegeneration ([@BHW128C83]). Within the graph theory framework, 2 regions might correlate with each other not only if they are structurally or functionally connected but also if they become atrophied at the same rate ([@BHW128C1]). Thus, since medial temporal, medial parietal, and limbic regions show atrophy since early stages of AD, it seems natural that they might strongly interact with other regions in the network that become atrophied with disease progression.

In the current study, we also compared global and local network topology between the patient groups. We observed that sMCI patients had a larger path length and reduced nodal closeness centrality in several regions compared with the other patients, indicating that they presented greater abnormalities in the communication or interaction between distant brain areas. Previous evidence suggests that the initial pathological changes occurring in AD do not target regions that are close to each other but rather distant brain areas ([@BHW128C92]), which are often connected by long and poorly myelinated axons. Hence, it is possible that these changes are more prominent in sMCI patients, which are potentially at earlier stages of AD. In contrast to the path length, the clustering coefficient was reduced in lMCIc, eMCIc, and AD patients compared with sMCI patients, suggesting that the loss of connections between neighboring areas reflects better the changes occurring in patients that are on the path to develop AD or already have dementia.

In the past few years, there has been increasing evidence showing that there is substantial heterogeneity among MCI patients. For instance, many MCI subjects remain stable for several years, while others show a fast progression to dementia and some can even fully reverse to normal cognition ([@BHW128C38]). Moreover, there are several non-AD pathologies that may produce amnestic MCI such as frontotemporal dementia ([@BHW128C78]), vascular dementia ([@BHW128C81]), and hippocampal sclerosis ([@BHW128C16]). In the current study, we observed heterogeneity in the network topology abnormalities between the MCI groups. Specifically, sMCI-1y patients showed evidence of increased clustering and almost no changes in the transitivity and modularity compared with controls (see [Supplementary Fig. 1](http://cercor.oxfordjournals.org/lookup/suppl/doi:10.1093/cercor/bhw128/-/DC1)), in contrast to the other MCI patients. It is possible that the sMCI-1y group included a mixture of subjects who remained stable, converted to dementia after a few years, had a non-AD related disorder or simply did not have any neurodegenerative disease (the cognitive deficits they presented were due to a transient medical condition). This heterogeneity might account for the lack of changes in the transitivity and modularity in sMCI-1y, in contrast to the other groups that were more homogeneous. Studies assessing network topology in MCI subjects should consider their results with respect to this important heterogeneity.

Although brain networks are sparse, current neuroimaging analyses build network representations that are continuous association matrices ([@BHW128C22]). For this reason, many studies apply a threshold to these matrices in an attempt to retain the true brain connections and remove the potentially spurious ones. One way of applying a threshold is to retain the connections that overcome a level of significance. However, this approach will result in different groups of subjects having different numbers of edges or connections. In the current study, we applied a threshold to the connectivity matrices of each group by retaining the most significant connections, while ensuring an equal number of connections across groups. Although this step would ideally consist of applying a single threshold to the connectivity matrices of different groups, there is currently no absolute way of determining which threshold is best ([@BHW128C22]). For this reason, we decided to test for group differences across a range of densities, similarly to previous studies ([@BHW128C33]; [@BHW128C80]). Since it does not make sense to compute topological measures in networks that have a random configuration, in the current study we defined the higher bound of this range using the small-world index, which indicates whether the networks are meaningfully organized. Our results showed that there were significant differences between groups at different densities, suggesting they were consistent.

We would like to highlight that the present study has some limitations. First, despite providing useful information, the analysis of structural covariance networks does not allow correlation analyses to be performed with clinical measures since there are no individual networks but only a network per group. Nevertheless, [@BHW128C72], [@BHW128C70]), [@BHW128C71]), and [@BHW128C73]) have overcome this limitation by providing a method that can create single-subject structural networks using structural MRI; this method could be considered in future graph theory studies assessing structural networks in large cohorts of AD and MCI patients. Secondly, we had limited longitudinal data regarding the clinical diagnosis of patients of only up to 3 years. Hence, it is possible that many of the individuals included in the sMCI group converted to dementia shortly after this period.

In conclusion, our study is the largest to date to assess structural network topology in stable MCI, progressive MCI, and AD by including 1008 patients and controls from 2 large multicenter cohorts. Our findings show, for the first time, that the transitivity and modularity are important graph theory measures that offer greater sensitivity to MCI and AD compared with the path length and clustering coefficient, which have been used more frequently in graph theory studies in AD. In addition, in contrast to previous studies, we provide a detailed description of nodal network changes in sMCI, lMCIc, eMCIc, and AD patients. Specifically, we show that while the nodal clustering showed widespread changes in AD patients, the closeness centrality detected alterations in several regions in all groups, showing overlapping changes in the hippocampi and amygdala and nonoverlapping changes in medial parietal and limbic areas in sMCI, lMCIc, eMCIc, and AD patients. These results offer an important glimpse into how AD progresses across different brain regions and ultimately leads to changes in global network organization.
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[^2]: Note: Means are followed by standard deviations. Differences in age, years of education, and MMSE scores were assessed using an analysis of variance (ANOVA). Differences in CDR scores were assessed using a Kruskal--Wallis test and differences in gender were assessed using a *χ*^2^ test. CTR, controls; sMCI, stable mild cognitive impairment after 1 year (sMCI-1y) or 3 years (sMCI); lMCIc, late mild cognitive impairment converters; eMCIc, early mild cognitive impairment converters; AD, Alzheimer\'s disease; MMSE, mini-mental state examination; CDR, clinical dementia rating scale.

[^3]: ^a^Significant differences between CTR and sMCI patients (*P* \< 0.05).

[^4]: ^b^Significant differences between sMCI-1y and AD patients (*P* \< 0.05).

[^5]: ^c^Significant differences between sMCI and AD patients (*P* \< 0.05).

[^6]: ^d^Significant differences between lMCIc and AD patients (*P* \< 0.05).

[^7]: ^e^Significant differences between eMCIc and AD patients (*P* \< 0.05).

[^8]: ^f^Significant differences between CTR and sMCI-1y patients (*P* \< 0.05).

[^9]: ^g^Significant differences between CTR and lMCIc patients (*P* \< 0.05).

[^10]: ^h^Significant differences between CTR and AD patients (*P* \< 0.05).

[^11]: ^i^Significant differences between sMCI-1y and sMCI patients (*P* \< 0.05).

[^12]: ^j^Significant differences between sMCI-1y and lMCIc patients (*P* \< 0.05).

[^13]: ^k^Significant differences between sMCI-1y and eMCIc patients (*P* \< 0.05).

[^14]: ^l^Significant differences between sMCI and eMCIc patients (*P* \< 0.05).

[^15]: ^m^Significant differences between lMCIc and eMCIc patients (*P* \< 0.05).

[^16]: ^n^Significant differences between CTR and eMCIc patients (*P* \< 0.05).

[^17]: ^o^Significant differences between sMCI and lMCIc patients (*P* \< 0.05).

[^18]: Note: CTR, controls; sMCI, stable mild cognitive impairment; lMCIc, late mild cognitive impairment converters; eMCIc, early mild cognitive impairment converters; AD, Alzheimer\'s disease; Lh, left hemisphere; Rh, right hemisphere; G, gyrus.

[^19]: Note: CTR, controls; sMCI, stable mild cognitive impairment; lMCIc, late mild cognitive impairment converters; eMCIc, early mild cognitive impairment converters; AD, Alzheimer\'s disease; Lh, left hemisphere; Rh, right hemisphere; G, gyrus.

[^20]: Note: Compared with controls, all patient groups showed an increased path length and modularity as well as changes in the nodal closeness centrality. The mean clustering coefficient was decreased only in lMCIc, eMCIc, and AD groups, while the nodal clustering showed the most prominent changes in AD patients by being decreased in a total of 21 regions compared with controls. Compared with sMCI patients, the other patient groups showed a decreased path length, mean clustering coefficient, and increased closeness centrality. There were also nodal clustering decreases in 1 region in AD patients compared with sMCI patients.

[^21]: Note: CTR, controls; sMCI, stable mild cognitive impairment; lMCIc, late mild cognitive impairment converters; eMCIc, early mild cognitive impairment converters; AD, Alzheimer\'s disease.

[^22]: Note: CTR, controls; sMCI, stable mild cognitive impairment; lMCIc, late mild cognitive impairment converters; eMCIc, early mild cognitive impairment converters; AD, Alzheimer\'s disease; Lh, left hemisphere; Rh, right hemisphere; G, gyrus. Differences between controls and AD patients survived corrections for multiple comparisons with FDR, while the other differences between groups were significant at an uncorrected level (*P* \< 0.05).
